Details of the Drug
General Information of Drug (ID: DMRP03X)
Drug Name |
1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Emodin anthrone; Emodinanthrone; 491-60-1; 1,3,8-Trihydroxy-6-methylanthrone; 1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one; UNII-77C500W1A2; 2,4,5-trihydroxy-7-methylanthracen-10(9H)-one; CHEMBL122192; 77C500W1A2; 1,6,8-trihydroxy-3-methyl-10-hydroanthracen-9-one; 9(10H)-Anthracenone, 1,3,8-trihydroxy-6-methyl-; Emodinanthranol; Emodinol; Protophyscihydrone; Frangulaemodinanthrone; Frangulaemodinanthranol; Frangula emodin anthrone; AC1L3UZ6; SCHEMBL6046328; DTXSID80197684; LAJSXCAVRQXZIO-UHFFFAOYSA-N; ZINC6070245; BCP29231
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 256.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||